Pharmacokinetics and interaction profile of topiramate: Review and comparison with other newer antiepileptic drugs

Epilepsia

Volumn 38, Issue SUPPL. 1, 1997, Pages

  Johannessen, S I ^a  

^a National Center for Epilepsy   (Norway)

Author keywords

Anticonvulsants; Carbamazepine; Drug monitoring; Drug therapy; Drug toxicity; Gaba pentin; Lamotrigine; Oxcarbazepine; Pharmacokinetics; Phenytoin; Topiramate; Valproate; Vigabatrin

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIGOXIN; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; EPILEPSY; HUMAN; PRIORITY JOURNAL;

EID: 0030893439     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb04512.x     Document Type: Conference Paper

References (43)

1. Cloyd J. Pharmacokinetic pitfalls of present antiepileptic drugs. Epilepsia 1991; 32(suppl 5):S53-65.
2. Scheyer RD, Cramer JA. Pharmacokinetics of antiepileptic drugs. Semin Neurol 1990; 10:414-21.
3. Thomson AH, Brodie MJ. Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 1992; 23:216-30.
4. Graves NM. Neuropharmacology and drug interactions in clinical practice. Epilepsia 1995; 36(suppl 2):S27-33.
5. Easterling DE, Zabzewski T, Moyer MD, et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988; 29:662.
6. Doose DR, Gisclon LG, Stellar SM, Riffits JM, Hills JF. The effect of food on the bioavailability of topiramate from 100- and 400-mg tablets in healthy male subjects. Epilepsia 1992; 33(suppl 3): 105.
7. Perucca E. Pharmacokinetic profile of topiramate in comparison with other antiepileptic drugs. Epilepsia 1996; 37(suppl 2):S8-13.
8. Gisclon LG, Riffits JM, Sica DA, Gehr T, Ruddley J. The phar- macokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharm Res 1993; 10(suppl):S397.
9. Gisclon LG, Curtin CR, Kramer LD. The steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994; 35(suppl 8):4.
10. Gisclon LG, Curtin CR, Kramer LD. A comparative study of the steady-state pharmacokinetics of phenytoin (Dilantin Kapseals brand) and of topiramate (Topamax) in male and female epileptic patients on monotherapy and during combination therapy. Pharm Res 1994; 22(suppl):S445.
11. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nayak RK. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy and during combination therapy. Epilepsia 1994; 35(suppl 8): 54.
12. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37:774-80.
13. Liao S, Rosenfeld WE, Palmer M, et al. Steady-state pharmacokinetics of Topamax (topiramate) and valproic acid in patients with epilepsy on monotherapy and during combination therapy. Pharm Res 1994: 10(suppl):405.
14. Liao S, Rosenfeld WE, Palmer M, et al. Steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy on monotherapy and during combination therapy. Epilepsia 1994; 35(suppl 8):117.
15. Doose DR, Rosenfeld WE, Schaefer P, el al. Evaluation of the potential pharmacokinetic interaction between topiramate and the oral contraceptive combination norethindrone/ethinyl estradiol. J Clin Pharmacol 1994; 34:1031.
16. Levy RH, Bishop F, Streeter AJ, et al. Explanation and prediction of drug interaclions with topiramate using a CYP450 inhibition spectrum. Epilepsia 1995; 35(suppl 4):47.
17. Richens A. Pharmacokinetics of lamotrigine. In: Richens A, ed. Clinical update on lamotrigine: a novel antiepileptic agent. Royal Tunbridge Wells: Wells Medical, 1992; 22-6.
18. Yau MK, Garnett WE, Wargin WA, Pellock JM. A single-dose, dose proportionality and bioequivaleni study of lamolrigine in normal volunleers. Epilepsia 1991; 32(suppl 3):8.
19. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42:535-41.
20. Messenheimer JA. Lamotrigine. Epilepsia 1995; 36(suppl 2):S87-94.
21. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46:152-76.
22. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995; 36(suppl 5):S1-7.
23. Yuen AWC, Land G, Weatherly BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33:511-3.
24. Jawad S, Yuen AWG, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single dose pharmacokinetics and initial one week exposure in refractory seizures. Epilepsy Res 1987; 1:196-201.
25. McLean MJ. Gabapentin. Epilepsia 1995; 36(suppl 2):S73-86.
26. Schmidt B. Gabapentin. In: Levy R, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:925-35.
27. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New trials in epilepsy management: the role of gabapentin. London: Royal Society of Medicine, 1993: 41-6.
28. Foot M, Wallace J. Gabapentin. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs. Amsterdam: Elsevier, 1991: 109-13.
29. Vollmer KO, Anhut H, Thomann P, Wagner F, Jahnchen D. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. In: Manelis J, Bental E, Loeber JN, Dreifuss FE, eds. The XVIIth epilepsy international symposium. New York: Raven Press, 1989:209-11 (Advances in epileptology, vol 17).
30. Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986; 36:830-9.
31. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Pharmacol 1989; 27:19-22.
32. Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36(suppl 2):S95-104.
33. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active Senantiomer. Clin Pharmacol Ther 1986; 40:581-6.
34. Thomson AH, Brodie MJ. Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 1992; 23:216-30.
35. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989; 27:27-37.
36. Hooper WD, Dickinson RG, Dunstan PR, Pendlebury SC, Eadie MJ. Oxcarbazepine: preliminary clinical and pharmacokinetic. studies on a new anticonvulsant. Clin Exp Neurol 1987; 24:105-12.
37. Kristensen O, Klitgaard NA, Jonsson B, Sindrup S. Pharmaco- kinetics of 10-OH carbazepine, the main metabolite of oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 1983; 68:145-50.
38. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35(suppl 3): S10-3.
39. Patsalos PN, Elyas AA, Zakrzewski JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990; 39:413-5.
40. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacological and therapeutic potential in epilepsy, trigeminal neurologic and affective disorders. Drugs 1993; 43:873-88.
41. 14C-oxcarbazepine in man. Xenobiotics 1986; 16:769-78.
42. Perucca E, Pisani F. Pharmacokinetics and interactions of the new antiepileptic drugs. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs. Amsterdam: Elsevier, 1991: 79-88.
43. Barruzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35(suppl 3):S14-9.